Medical Education Library

Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

This supplement is sponsored by Salix Pharmaceuticals.


Click to read supplement.

In this supplement to GI & Hepatology news , Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

  • IBS-D diagnosis and treatment challenges
  • The role of microbial imbalance and altered gut microbiota
  • A treatment option for relief of IBS-D symptoms

Click to read supplement.


Next Article: